Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kurt Kuhlman

Physical Medicine & Rehabilitation Lima, OH Doctor of Osteopathy

NPI 1144201013 CMS profile 850927

939 W Market St, Ste 1, Lima, OH 45805

Open in the dashboard

General payments

$45,981

579 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kurt Kuhlman of Lima, OH is reported in the CMS Open Payments database as having received $45,981 across 579 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,314 55
2024 General $8,157 79
2023 General $7,949 86
2022 General $5,721 102
2021 General $15,702 104
2020 General $6,328 70
2019 General $810 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kurt Kuhlman
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Kurt Kuhlman were reported at $1,314. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Kurt Kuhlman Physical Medicine & Rehabilitation median Middle half National median
2019 $810 $133 $45–$390 $163
2020 $6,328 $88 $29–$272 $114
2021 $15,702 $116 $33–$360 $132
2022 $5,721 $123 $40–$378 $149
2023 $7,949 $131 $43–$396 $160
2024 $8,157 $141 $45–$409 $164
2025 $1,314 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $24,734 128 payments
  2. AbbVie, Inc. $17,808 206 payments
  3. Pfizer Inc. $594 41 payments
  4. Amgen Inc. $348 34 payments
  5. Merz North America, Inc. $244 13 payments
  6. Upsher-Smith Laboratories LLC $208 13 payments
  7. Galderma Laboratories, L.P. $207 13 payments
  8. Lilly USA, LLC $203 14 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $199 22 payments
  10. Merz Pharmaceuticals, LLC $198 12 payments
  11. Other $1,238 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $37,114 24 payments
  2. Food and Beverage $7,270 535 payments
  3. Travel and Lodging $1,478 4 payments
  4. Education $120 16 payments
Products named General payments · program years 2019–2025
  1. BOTOX Neuroscience $37,174 41 payments
  2. UBRELVY Neuroscience $1,816 16 payments
  3. UBRELVY Neuroscience $1,063 73 payments
  4. BOTOX Hyperhydrosis $884 86 payments
  5. QULIPTA $873 68 payments
  6. BOTOX Botox Therapeutic $869 56 payments
  7. NURTEC ODT Pain $497 34 payments
  8. NURTEC ODT Primary Care $368 37 payments
  9. AIMOVIG $356 35 payments
  10. ZAVZPRET $331 22 payments
  11. Other $3,076 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,457

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$203,444

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

34.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 93 $148,325
Aimovig Autoinjector Erenumab-Aooe Brand 15 $16,284
Lyrica Pregabalin Brand 13 $9,067
Xeomin Incobotulinumtoxina Brand 12 $6,633
Pregabalin Generic 193 $5,012
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 185 $4,316
Gabapentin Generic 92 $2,451
Duloxetine Hcl Generic 80 $1,711
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 70 $1,252
Tizanidine Hcl Generic 39 $1,154

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$459,363

Of which drugs: $260,068

Medicare patients

495

Average age 72

Services billed

55,500

277 women, 218 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Ischemic heart disease 45%
Diabetes 38%
Depression 31%
Chronic kidney disease 26%
Atrial fibrillation 25%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 62 48,000 $237,523
Injection, methocarbamol, up to 10 ml J2800 Office 47 82 $389
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 47 84 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $7,387
$7,387 93 48,000
QULIPTA
  • AbbVie, Inc. $114
$114 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $61
  • Galderma Laboratories, L.P. $50
$110 — —
UBRELVY
  • AbbVie, Inc. $94
$94 — —
NURTEC ODT
  • PFIZER INC. $93
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

579 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record